Abstract
We describe features of a patient that broadens the clinical and pathological spectrum of neurofilament inclusion disease (NFID). The patient was a 52-year-old man with a 5–6 year history of progressive, asymmetrical spastic weakness of the upper and lower extremities; l-DOPA-unresponsive parkinsonism; and SPECT evidence of asymmetrical frontoparietal and basal ganglia hypoperfusion. The brain had marked frontoparietal parasagittal cortical atrophy, including the motor cortex, with histopathological evidence of neurofilament- and α-internexin-immunoreactive neuronal inclusions. The corticospinal tract had degeneration, but there was minimal lower motor neuron pathology. There was also severe neuronal loss and gliosis in the posterolateral putamen and the substantia nigra, mimicking multiple system atrophy; however, glial cytoplasmic inclusions were not detected with α-synuclein immunohistochemistry. This case extends the clinical and pathological spectrum of NFID to include cases with predominant parkinsonian and pyramidal features.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bigio EH, Lipton AM, White CL 3rd, Dickson DW, Hirano A (2003) Frontotemporal and motor neurone degeneration with neurofilament inclusion bodies: additional evidence for overlap between FTD and ALS. Neuropathol Appl Neurobiol 29:239–253
Bunina TL (1962) On intracellular inclusions in familial amyotrophic lateral sclerosis. Zh Nevropatol Psikhiatr Im S S Korsakova 62:1293–1299
Cairns NJ, Grossman M, Arnold SE, et al (2004) Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology 63:1376–1384
Cairns NJ, Uryu K, Bigio EH, et al (2004) Alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol 108:213–223
Cairns NJ, Zhukareva V, Uryu K, et al (2004) Alpha-Internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am J Pathol 164:2153–2161
Chou SM, Wang HS, Taniguchi A (1996) Role of SOD-1 and nitric oxide/cyclic GMP cascade on neurofilament aggregation in ALS/MND. J Neurol Sci 139 Suppl:16–26
Dickson DW (2003) Neurodegeneration: the molecular pathology of dementia and movement disorders. ISN Neuropath Press, Basel, pp 1–414
Dickson DW, Liu W, Hardy J, et al (1999) Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol 155:1241–1251
Evans J, Sumners C, Moore J, Huentelman MJ, Deng J, Gelband CH, Shaw G (2002) Characterization of mitotic neurons derived from adult rat hypothalamus and brain stem. J Neurophysiol 87:1076–1085
Gearing M, Castellano AA, Hunter SB, et al (2003) Unusual neuropathologic findings in a case of primary lateral sclerosis. J Neuropathol Exp Neurol 62:555
Gilman S, Low P, Quinn N, et al (1999) Consensus on the diagnosis of multi-system atrophy. Neurologia 14:425–428
Jackson M, Lennox G, Lowe J (1996) Motor neurone disease-inclusion dementia. Neurodegeneration 5:339–350
Josephs KA, Holton JL, Rossor MN, et al (2003) Neurofilament inclusion body disease: a new proteinopathy. Brain 126:2291–303
Josephs KA, Holton JL, Rossor MN, et al (2004) Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathol Appl Neurobiol 30:369–373
Lantos PL (1998) The definition of multiple system atrophy: a review orf recent developments. J Neuropathol Exp Neurol 57:1099–1111
Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121–1159
Lowe J (1998) Establishing a pathological diagnosis in degenerative dementias. Brain Pathol 8:403–406
Mackenzie IR, Feldman H (2004) Neurofilament inclusion body disease with early onset frontotemporal dementia and primary lateral sclerosis. Clin Neuropathol 23:183–93
Mills CK (1900) A rare case of unilateral progressive ascending paralysis probably presenting a new form of degenerative disease. J Nerv Ment Dis 27:195–200
Pachter JS, Liem RK (1985) Alpha-Internexin, a 66-kD intermediate filament-binding protein from mammalian central nervous tissues. J Cell Biol 101:1316–1322
Quinn N (1989) Multiple system atrophy—the nature of the beast. J Neurol Neurosurg Psychiatry Suppl: 78–89
Rossor MN, Revesz T, Lantos PL, Warrington EK (2000) Semantic dementia with ubiquitin-positive tau-negative inclusion bodies. Brain 123:267–276
Sima AA, Caplan M, D’Amato CJ, Pevzner M, Furlong JW (1993) Fulminant multiple system atrophy in a young adult presenting as motor neuron disease. Neurology 43:2031–2035
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840
Sudo S, Fukutani Y, Matsubara R, et al (2002) Motor neuron disease with dementia combined with degeneration of striatonigral and pallidoluysian systems. Acta Neuropathol 103:521–525
Swash M, Desai J, Misra VP (1997) What is primary lateral sclerosis? J Neurol Sci 17:220–224
Taniwaki T, Minohara M, Hara H, Ohyagi Y, Yamada T, Kira JI (2000) Striatonigral degeneration with motor neuron disease. J Neurol 247:395–396
Author information
Authors and Affiliations
Corresponding author
Additional information
Gerry Shaw holds equity in EnCor Biotechnology Inc., a company commercializing the alpha-internexin antibody used in this study, and may benefit by receiving royalties or equity growth.
Rights and permissions
About this article
Cite this article
Josephs, K.A., Uchikado, H., McComb, R.D. et al. Extending the clinicopathological spectrum of neurofilament inclusion disease. Acta Neuropathol 109, 427–432 (2005). https://doi.org/10.1007/s00401-004-0974-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00401-004-0974-4